`
`
`
` ‘L
`
`
`I A Meefing Ijbraryllpilimt X |+ v
`6909:
`Q.
`httpszeetinglibraryascoorgfrecordeSSAQ/abstract
`
`
`
`ASCO' Mee’r'ng Library
`
`
`Sign In Q CD
`
`Ipilimumab for recurrent glioblastoma (GBM).
`
`Add to Collection 0
`
`Abstract
`
`
`Authors:
`
`Lauren R. Schaff, Andrew B. Lassman, Samuel A Goldlust, Timothy Francis Cloughesy,
`Samuel Singer, Gary K Schwartz, Fabio Massaitl Iwamoto; Columbia University Medical
`Center, New York, NY:John Theurer Cancer Center, Hackensack, N]; University of
`California, Los Angeles, Los Angeles, CA
`
`Abstract Disclosures
`
`Background:
`Currently available treatments for recurrent glioblastoma (GBM) are inadequate, and
`median survival is approximately 6 months. Ipilimumab (ipi) is an immune modulator
`that inhibits (FLA-4 and is active in refractory melanoma. including brain metastases.
`
`Methods:
`
`We retrospectively reviewed medical records of patients treated with ipi for recurrent
`GBM. and explored safety. response, and survival using Kaplan-Meier methodology.
`
`Results:
`
`There were 10 patients (6 men), median age 55 years (range, 41 -6S). All received prior
`radiotherapy and temozolomide. and 9 received prior bevaclzumab. lpi (3mg/kg/dose)
`was administered for 1St (l ). 2nd {4), 3"d {4), or 6mm recurrence. Bevacizumab was
`administered concurrently to all patients to reduce corticosteroid requirements that can
`blunt ipi effect. Eight patents received concurrent GM-CSF. Dther concurrent
`chemotherapy included nitrosoureas (5). carboplatin (1}, temozolomide (1). or lapatinib
`(1). Corticosteroids (dexamethasone, 0.75 7 4.0 mg/day) were administered concurrently
`in 4. All patients were evaluated for toxicity. One experienced fever, elevated LDH, and
`transaminitis. There were no other significant toxicities, specifically no rash,
`endocrinopathies, or electrolyte abnormalities. Four patients recently started treatment
`and were not evaluable for efficacy analyses. Among the other 6 patients, best response
`was stable disease in 4, and progressive disease in 2; median progression free survival
`(PFS) was 2.2 months and overall survival (OS) was 5.1 months.
`
`Conclusions:
`
`Meeting:
`
`Session
`Title:
`
`Track:
`
`Subtrack:
`
`2014mm
`Annual
`Meen'ng
`
`Publication
`Only: Central
`Nervous
`System
`Tumors
`
`Central
`Nervous
`System
`Tumors
`
`Central
`Nervous
`System
`Tumors
`
`Abstract #:
`
`e13026
`
`Citation:
`
`lCIin Oncol 31
`20l4 [supp|:
`abstr E13026)
`
`Glioblastoma
`
`Drug therapy
`
`Radiation therapy
`
`Granulocyte macrophage colony
`stimulating factor
`
`2014 Annual Meeting
`Proceedings Notices
`
`@lleE
`
`Ipilimumab can be administered safelyto patients with GBM with concurrent GM-CSF,
`bevacizumab. nitrosoureas, and other therapies. Concurrent bevacizumab may reduce
`corticosteroid requirements. Treatment earlier in the disease course merits
`investigation.
`
`
`
`
`
`
`